LYTACs
Pioneering the next generation of protein degradation therapeutics through innovative LYsosome TArgeting Chimeras
Need Help?
Overview
LYTACs, or LYsosome TArgeting Chimeras, are cutting-edge bifunctional molecules designed to target and degrade specific proteins outside cells by directing them to the lysosome, a cellular organelle responsible for degradation.
By harnessing the cell’s natural lysosomal degradation pathway, LYTACs can target and eliminate disease-associated proteins present outside of cells, including those involved in inflammation, cancer, and neurodegenerative disorders.
How LYTACs Work
As research in LYTAC technology continues to advance, it holds significant promise for transforming the landscape of medicine and improving patient outcomes.
Key Components
Lysosomal Receptor Ligand
Binds to specific receptors on the lysosome surface to initiate targeting
Target Protein Binder
Specifically recognizes and binds to the disease-associated protein
Linker
Connects both entities while maintaining optimal functionality
Therapeutic Applications
Inflammation
Targeting inflammatory proteins for autoimmune disorders
Cancer
Eliminating oncogenic proteins in tumor environments
Neurodegeneration
Clearing toxic protein aggregates in the brain
LifeSensors Solutions
LifeSensors offers unique and physiologically relevant target ubiquitination and degradation assays that allow rapid characterization of LYTACs for their specificity and potency.
LifeSensors helps you study LYTACs to make breakthrough discoveries and pave the way to novel therapeutics.
Research Resources
Directed Evolution of Genetically Encoded LYTACs
For cell-mediated delivery
Nano-LYTACs for Degradation of Membrane Proteins
And inhibition of CD24/Siglec-10 signaling pathway